Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed relapsed or refractory HIV-associated non-Hodgkin lymphoma (NHL)~  * Must have histologic or cytologic documentation of prior AIDS-associated NHL (i.e., at time of diagnosis) for clinically relapsed and/or refractory disease for which biopsy is not feasible~ * Must have documented HIV seropositivity~ * Must have documentation of Epstein-Barr Virus (EBV)- and/or human herpes virus-8 (HHV-8)- positive infection within the lymphoma (i.e., LMP-1, LANA expression, or positive Epstein-Barr-encoded RNAs \[EBERs\])~PATIENT CHARACTERISTICS:~Inclusion criteria:~* ECOG performance status (PS) 0-2 OR Karnofsky PS 50-100%~* Life expectancy \> 2 months~* ANC ≥ 1,000/mm³\* (growth factor support allowed)~* Hemoglobin ≥ 8.0 g/dL\* (growth factor support allowed)~* Platelet count ≥ 100,000/mm³~* Total bilirubin ≤ 1.5 mg/dL~* AST/ALT ≤ 2.5 times institutional upper limit of normal (ULN)~* Serum creatinine ≤ ULN~* Creatinine clearance ≥ 50 mL/min~* Negative pregnancy test~* Not pregnant or nursing~* Fertile patients must use effective contraception NOTE: \*Patients with lymphomatous involvement of the bone unable to meet hematologic criteria are allowed~Exclusion criteria:~* Peripheral neuropathy ≥ grade 2~* Uncontrolled intercurrent illness including, but not limited to, any of the following:~  * Ongoing or active infection~    * Opportunistic infections controlled by antimicrobial or suppressive therapy allowed, unless the investigator judges the infection likely to become life-threatening in the setting of multi-agent chemotherapy~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * NYHA class III or IV heat failure~ * Myocardial infarction within the past 6 months~ * Uncontrolled angina~ * Severe uncontrolled ventricular or other cardiac arrhythmias~ * Acute ischemia or active conduction system abnormalities by ECG~ * Serious psychiatric or medical illness, that would interfere with study compliance~* Social situations that would interfere with study compliance~* Acute active HIV-associated opportunistic infection requiring antibiotic treatment~  * Mycobacterium avium or candidiasis allowed unless concurrent therapy with moderate-to-strong CYP3A4 inducers or inhibitors is required~ * Chronic myelosuppressive agent therapy allowed provided hematologic criteria are met~* Hypersensitivity to compounds of similar chemical or biological composition to bortezomib, boron, mannitol, ifosfamide, carboplatin, or etoposide~* Concurrent malignancy except carcinoma in situ of the cervix, in situ anal cancer, nonmetastatic nonmelanoma skin cancer, or Kaposi's sarcoma not requiring systemic chemotherapy~* Active hepatitis B infection (hepatitis B surface antigen-positive), unless 1 of the following criteria are met:~  * Able to start dual anti-hepatitis B adefovir and telbivudine therapy prior to study~ * Receiving dual anti-hepatitis B therapy for at least 12 weeks prior to study with either agent active against HIV (i.e., entecavir, tenofovir, lamivudine, or emtricitabine)~* Concurrent grapefruit juice/fruit or green tea~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior adverse effects due to agents administered more than 3 weeks earlier~* Glucocorticoid therapy within the past 3 weeks allowed~* More than 3 weeks since prior chemotherapy~* More than 2 weeks since prior radiotherapy~* More than 14 days since prior and no other concurrent investigational agents (other than bortezomib)~* No concurrent moderate-to-strong CYP3A4 inducers or inhibitors other than protease inhibitors~* Concurrent stable (at least 12 weeks) antiretroviral regimen allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- CD20+ Non-Hodgkin Lymphoma (Type: EXPERIMENTAL): Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, rituximab 375mg/m2 on Day 1 of a 21-day cycle.
- CD20- Non-Hodgkin Lymphoma (Type: EXPERIMENTAL): Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, 21-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).